How much funding has Averna Therapeutics raised?

Averna Therapeutics has raised $82.0M in total funding, most recently a Series A round.

When was Averna Therapeutics founded?

Averna Therapeutics was founded in 2022.

Where is Averna Therapeutics headquartered?

Averna Therapeutics is headquartered in Watertown, Massachusetts, United States.

What industry is Averna Therapeutics in?

Averna Therapeutics operates in Life Sciences, Biotech.

How many employees does Averna Therapeutics have?

Averna Therapeutics has 11-50 employees.

Averna Therapeutics

Q: Who are Averna Therapeutics's investors?

Averna Therapeutics's investors include Novartis Venture Fund, Delos Capital, OrbiMed, Insight Partners.

Delivering what's next in genetic medicine.

Watertown, United States · Founded 2022 · $82.0M raised

Life Sciences

Biotech

Headquarters: Watertown, Massachusetts
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: avernatx.com
Total Funding: $82.0M
Last Round: $82.0M Series AJun 2024
Rounds: 1

About

Averna Therapeutics (formerly Exsilio Therapeutics) is a biotechnology company developing RNA/lipid nanoparticle (LNP)-based genomic medicines designed to durably insert any gene or genetic instruction of interest into cells. The company's platform leverages site-specific retrotransposons — nature's precision gene insertion system — to safely integrate large sets of genetic instructions at safe harbor genomic locations without disrupting cell function. Averna's all-RNA system, delivered by LNPs, aims to expand the reach of genetic medicines beyond what viral approaches can achieve, broadening addressable diseases and patient populations. The company was recognized as a 2025 Endpoints 11 Most Promising Biotech.

Summary

Averna Therapeutics is a Life Sciences company based in Watertown, United States, founded in 2022. It has raised $82.0M in total across 1 round, most recently a $82.0M Series A round in Jun 2024. Investors include Novartis Venture Fund, Delos Capital and OrbiMed.